NM_001077418.3(TMEM231):c.168G>T (p.Glu56Asp) AND Inborn genetic diseases

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Feb 10, 2022
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV002827104.9

Allele description [Variation Report for NM_001077418.3(TMEM231):c.168G>T (p.Glu56Asp)]

NM_001077418.3(TMEM231):c.168G>T (p.Glu56Asp)

Genes:

LOC130059440:ATAC-STARR-seq lymphoblastoid silent region 7724 [Gene]
TMEM231:transmembrane protein 231 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

16q23.1

Genomic location:

Preferred name:

NM_001077418.3(TMEM231):c.168G>T (p.Glu56Asp)

HGVS:

NC_000016.10:g.75555945C>A
NG_033109.1:g.5342G>T
NG_193861.1:g.103C>A
NM_001077416.2:c.327G>T
NM_001077418.3:c.168G>TMANE SELECT
NP_001070884.2:p.Glu109Asp
NP_001070886.1:p.Glu56Asp
NC_000016.9:g.75589843C>A
NM_001077416.1:c.255G>T
NR_074083.2:n.211G>T

Protein change:

E109D

Molecular consequence:

NM_001077416.2:c.327G>T - missense variant - [Sequence Ontology: SO:0001583]
NM_001077418.3:c.168G>T - missense variant - [Sequence Ontology: SO:0001583]
NR_074083.2:n.211G>T - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:: Inborn genetic diseases
Identifiers:: MeSH: D030342; MedGen: C0950123

Recent activity

Clear Turn Off Turn On

Transcriptional activity of a T-ALL PDX line following in vitro treatment with i...
Transcriptional activity of a T-ALL PDX line following in vitro treatment with idasanutlin, navitoclax (ABT-263), or combination therapy
Transcriptional activity of a T-ALL PDX line following in vitro treatment with idasanutlin, navitoclax (ABT-263), or combination therapy

BioProject

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV003615050	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Feb 10, 2022)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV003615050

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Feb 10, 2022)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV003615050.2

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The c.255G>T (p.E85D) alteration is located in exon 1 (coding exon 1) of the TMEM231 gene. This alteration results from a G to T substitution at nucleotide position 255, causing the glutamic acid (E) at amino acid position 85 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Jul 15, 2024

ClinVar

Relating variation to medicine